Skip to main content

Articles

Page 2 of 9

  1. Neurodegenerative diseases are a set of progressive and currently incurable diseases that are primarily caused by neuron degeneration. Neurodegenerative diseases often lead to cognitive impairment and dyskines...

    Authors: Vaibhav Sharma, Fredrik Nikolajeff and Saroj Kumar
    Citation: Translational Neurodegeneration 2023 12:7
  2. Alzheimer’s disease (AD) is a progressive multifaceted neurodegenerative disorder for which no disease-modifying treatment exists. Neuroinflammation is central to the pathology progression, with evidence sugge...

    Authors: Luis Enrique Arroyo-García, Sara Bachiller, Rocío Ruiz, Antonio Boza-Serrano, Antonio Rodríguez-Moreno, Tomas Deierborg, Yuniesky Andrade-Talavera and André Fisahn
    Citation: Translational Neurodegeneration 2023 12:6
  3. The impact of coronavirus disease 2019 (COVID-19) pandemic on patients with neurodegenerative diseases and the specific neurological manifestations of COVID-19 have aroused great interest. However, there are s...

    Authors: Pei Huang, Lin-Yuan Zhang, Yu-Yan Tan and Sheng-Di Chen
    Citation: Translational Neurodegeneration 2023 12:5

    The Correction to this article has been published in Translational Neurodegeneration 2023 12:23

  4. Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observ...

    Authors: Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Simon Lam, Halil Aziz Velioglu, Hong Yang, Ebru Coskun, Ezgi Idil, Rahim Nogaylar, Ahmet Ozsimsek, Cemil Bayram, Ismail Bolat, Sena Oner, Ozlem Ozdemir Tozlu…
    Citation: Translational Neurodegeneration 2023 12:4
  5. Increased neurofilament levels in biofluids are commonly used as a proxy for neurodegeneration in several neurodegenerative disorders. In this study, we aimed to investigate the distribution of neurofilaments ...

    Authors: Irene Frigerio, Max A. Laansma, Chen-Pei Lin, Emma J. M. Hermans, Maud M. A. Bouwman, John G. J. M. Bol, Yvon Galis-de Graaf, Dagmar H. Hepp, Annemieke J. M. Rozemuller, Frederik Barkhof, Wilma D. J. van de Berg and Laura E. Jonkman
    Citation: Translational Neurodegeneration 2023 12:3
  6. Authors: Ankit Verma, Anna Shteinfer-Kuzmine, Nikita Kamenetsky, Srinivas Pittala, Avijit Paul, Edna Nahon Crystal, Alberto Ouro, Vered Chalifa-Caspi, Swaroop Kumar Pandey, Alon Monsonego, Noga Vardi, Shira Knafo and Varda Shoshan-Barmatz
    Citation: Translational Neurodegeneration 2023 12:2

    The original article was published in Translational Neurodegeneration 2022 11:58

  7. Ribosomal protein S6 kinase 1 (S6K1) is a serine–threonine kinase that has two main isoforms: p70S6K (70-kDa isoform) and p85S6K (85-kDa isoform). p70S6K, with its upstream mammalian target of rapamycin (mTOR)...

    Authors: Jia-Bing Li, Xiao-Yu Hu, Mu-Wen Chen, Cai-Hong Xiong, Na Zhao, Yan-Hui Ge, Hao Wang, Xiao-Ling Gao, Nan-Jie Xu, Lan-Xue Zhao, Zhi-Hua Yu, Hong-Zhuan Chen and Yu Qiu
    Citation: Translational Neurodegeneration 2023 12:1
  8. Alzheimer's disease (AD) exhibits mitochondrial dysfunctions associated with dysregulated metabolism, brain inflammation, synaptic loss, and neuronal cell death. As a key protein serving as the mitochondrial g...

    Authors: Ankit Verma, Anna Shteinfer-Kuzmine, Nikita Kamenetsky, Srinivas Pittala, Avijit Paul, Edna Nahon Crystal, Alberto Ouro, Vered Chalifa-Caspi, Swaroop Kumar Pandey, Alon Monsonego, Noga Vardi, Shira Knafo and Varda Shoshan-Barmatz
    Citation: Translational Neurodegeneration 2022 11:58

    The Correction to this article has been published in Translational Neurodegeneration 2023 12:2

  9. Aducanumab (Adu), which is a human IgG1 monoclonal antibody that targets oligomer and fibril forms of beta-amyloid, has been reported to reduce amyloid pathology and improve impaired cognition after administra...

    Authors: Chanho Kong, Eun-Jeong Yang, Jaewoo Shin, Junwon Park, Si-Hyun Kim, Seong-Wook Park, Won Seok Chang, Chang-Han Lee, Hyunju Kim, Hye-Sun Kim and Jin Woo Chang
    Citation: Translational Neurodegeneration 2022 11:57
  10. Amyotrophic lateral sclerosis (ALS) is a disease characterized by upper and lower motor neuron (MN) loss with a signature feature of cytoplasmic aggregates containing TDP-43, which are detected in nearly all p...

    Authors: Sarah Lépine, Maria José Castellanos-Montiel and Thomas Martin Durcan
    Citation: Translational Neurodegeneration 2022 11:56
  11. Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are m...

    Authors: Gillian Bonvicini, Stina Syvänen, Ken G. Andersson, Merja Haaparanta-Solin, Francisco López-Picón and Dag Sehlin
    Citation: Translational Neurodegeneration 2022 11:55
  12. Amyotrophic lateral sclerosis (ALS) is an adult-onset paralytic disease characterized by progressive degeneration of upper and lower motor neurons in the motor cortex, brainstem and spinal cord. Motor neuron d...

    Authors: Winanto Ng and Shi-Yan Ng
    Citation: Translational Neurodegeneration 2022 11:54
  13. Axons, crucial for impulse transmission and cellular trafficking, are thought to be primary targets of neurodegeneration in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Axonal degeneration occ...

    Authors: Yasmine Y. Fathy, Laura E. Jonkman, John J. Bol, Evelien Timmermans, Allert J. Jonker, Annemieke J. M. Rozemuller and Wilma D. J. van de Berg
    Citation: Translational Neurodegeneration 2022 11:52
  14. Deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM) has shown potential for the treatment of mild-to-moderate Alzheimer’s disease (AD). However, there is little evidence of whether NBM-DBS can...

    Authors: Yin Jiang, Tian-Shuo Yuan, Ying-Chuan Chen, Peng Guo, Teng-Hong Lian, Yu-Ye Liu, Wei Liu, Yu-Tong Bai, Quan Zhang, Wei Zhang and Jian-Guo Zhang
    Citation: Translational Neurodegeneration 2022 11:51
  15. Neurodegenerative disorders are one of the most common causes of disability and represent 6.3% of the global burden of disease. Among them, Alzheimer’s, Parkinson’s, and Huntington’s diseases cause cognitive d...

    Authors: Francesca Natale, Salvatore Fusco and Claudio Grassi
    Citation: Translational Neurodegeneration 2022 11:50
  16. Microbiome-gut-brain axis may be involved in the progression of age-related cognitive impairment and relevant brain structure changes, but evidence from large human cohorts is lacking. This study was aimed to ...

    Authors: Xinxiu Liang, Yuanqing Fu, Wen-ting Cao, Zhihong Wang, Ke Zhang, Zengliang Jiang, Xiaofang Jia, Chun-ying Liu, Hong-rou Lin, Haili Zhong, Zelei Miao, Wanglong Gou, Menglei Shuai, Yujing Huang, Shengdi Chen, Bing Zhang…
    Citation: Translational Neurodegeneration 2022 11:49
  17. This literature review investigates the significant overlap between myelin-repair signaling pathways and pathways known to contribute to hallmark pathologies of Alzheimer’s disease (AD). We discuss previously ...

    Authors: Lauren Rose Hirschfeld, Shannon L. Risacher, Kwangsik Nho and Andrew J. Saykin
    Citation: Translational Neurodegeneration 2022 11:47
  18. Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease that affects neurons in the central nervous system and the spinal cord. As in many other neurodegenerative disorders, ...

    Authors: Panlin Liao, Yanchun Yuan, Zhen Liu, Xiaorong Hou, Wanzhen Li, Jin Wen, Kexuan Zhang, Bin Jiao, Lu Shen, Hong Jiang, Jifeng Guo, Beisha Tang, Zhuohua Zhang, Zhonghua Hu and Junling Wang
    Citation: Translational Neurodegeneration 2022 11:46
  19. The ε4 allele of apolipoprotein E (APOE ε4) is the strongest known genetic risk factor for late-onset Alzheimer’s disease (AD), associated with amyloid pathogenesis. However, it is not clear how APOE ε4 accelerat...

    Authors: Hongwon Kim, Siyoung Kim, Byounggook Cho, Jaein Shin and Jongpil Kim
    Citation: Translational Neurodegeneration 2022 11:45
  20. Aberrant aggregation of α-synuclein (α-syn) is a key pathological feature of Parkinson’s disease (PD), but the precise role of intestinal α-syn in the progression of PD is unclear. In a number of genetic Drosophi...

    Authors: Wei Liu, Kah-Leong Lim and Eng-King Tan
    Citation: Translational Neurodegeneration 2022 11:44
  21. Continuous drug delivery (CDD) is used in moderately advanced and late-stage Parkinson’s disease (PD) to control motor and non-motor fluctuations (‘OFF’ periods). Transdermal rotigotine is indicated for early ...

    Authors: Silvia Rota, Daniele Urso, Daniel J. van Wamelen, Valentina Leta, Iro Boura, Per Odin, Alberto J. Espay, Peter Jenner and K. Ray Chaudhuri
    Citation: Translational Neurodegeneration 2022 11:43
  22. Alzheimer’s disease (AD) is a progressive neurodegenerative disease with phenotypic changes closely associated with both genetic variants and imaging pathology. Brain imaging biomarker genomics has been develo...

    Authors: Lanlan Li, Xianfeng Yu, Can Sheng, Xueyan Jiang, Qi Zhang, Ying Han and Jiehui Jiang
    Citation: Translational Neurodegeneration 2022 11:42
  23. Aberrant DNA methylation patterns have been observed in neurodegenerative diseases, including Alzheimer's disease (AD), and dynamic changes in DNA methylation are closely associated with the onset and progress...

    Authors: Hanseul Park, Jaein Shin, Yunkyung Kim, Takashi Saito, Takaomi C. Saido and Jongpil Kim
    Citation: Translational Neurodegeneration 2022 11:41
  24. Furin is an important mammalian proprotein convertase that catalyzes the proteolytic maturation of a variety of prohormones and proproteins in the secretory pathway. In the brain, the substrates of furin inclu...

    Authors: Yi Zhang, Xiaoqin Gao, Xue Bai, Shanshan Yao, Yan-Zhong Chang and Guofen Gao
    Citation: Translational Neurodegeneration 2022 11:39
  25. Authors: Matilde Bongianni, Mauro Catalan, Daniela Perra, Elena Fontana, Francesco Janes, Claudio Bertolotti, Luca Sacchetto, Stefano Capaldi, Matteo Tagliapietra, Paola Polverino, Valentina Tommasini, Giulia Bellavita, Elham Ataie Kachoie, Roberto Baruca, Andrea Bernardini, Mariarosaria Valente…
    Citation: Translational Neurodegeneration 2022 11:38

    The original article was published in Translational Neurodegeneration 2022 11:37

  26. In patients with Parkinson’s disease (PD), real-time quaking-induced conversion (RT-QuIC) detection of pathological α-synuclein (α-syn) in olfactory mucosa (OM) is not as accurate as in other α-synucleinopathi...

    Authors: Matilde Bongianni, Mauro Catalan, Daniela Perra, Elena Fontana, Francesco Janes, Claudio Bertolotti, Luca Sacchetto, Stefano Capaldi, Matteo Tagliapietra, Paola Polverino, Valentina Tommasini, Giulia Bellavita, Elham Ataie Kachoie, Roberto Baruca, Andrea Bernardini, Mariarosaria Valente…
    Citation: Translational Neurodegeneration 2022 11:37

    The Correction to this article has been published in Translational Neurodegeneration 2022 11:38

  27. Neurological disorders (NDs) are characterized by progressive neuronal dysfunction leading to synaptic failure, cognitive impairment, and motor injury. Among these diseases, Alzheimer's disease (AD), Parkinson...

    Authors: Margrethe A. Olesen, Francisca Villavicencio-Tejo and Rodrigo A. Quintanilla
    Citation: Translational Neurodegeneration 2022 11:36
  28. Neuronal dysfunction and degeneration linked to α-synuclein (αS) pathology is thought to be responsible for the progressive nature of Parkinson’s disease and related dementia with Lewy bodies. Studies have ind...

    Authors: Scott C. Vermilyea, Anne Christensen, Joyce Meints, Balvindar Singh, Héctor Martell-Martínez, Md. Razaul Karim and Michael K. Lee
    Citation: Translational Neurodegeneration 2022 11:34
  29. Most neurodegenerative disorders are diseases of protein homeostasis, with misfolded aggregates accumulating. The neurodegenerative process is mediated by numerous metabolic pathways, most of which lead to apo...

    Authors: Kareem Khalaf, Paolo Tornese, Antoniangela Cocco and Alberto Albanese
    Citation: Translational Neurodegeneration 2022 11:33
  30. Accumulation of impaired mitochondria and energy metabolism disorders are non-negligible features of both aging and age-related neurodegeneration, including Alzheimer’s disease (AD). A growing number of studie...

    Authors: Kuan Zeng, Xuan Yu, Yacoubou Abdoul Razak Mahaman, Jian-Zhi Wang, Rong Liu, Yi Li and Xiaochuan Wang
    Citation: Translational Neurodegeneration 2022 11:32
  31. Axonal degeneration and defects in neuromuscular neurotransmission represent a pathological hallmark in spinal muscular atrophy (SMA) and other forms of motoneuron disease. These pathological changes do not on...

    Authors: Chunchu Deng, Sebastian Reinhard, Luisa Hennlein, Janna Eilts, Stefan Sachs, Sören Doose, Sibylle Jablonka, Markus Sauer, Mehri Moradi and Michael Sendtner
    Citation: Translational Neurodegeneration 2022 11:31
  32. The molecular heterogeneity of Alzheimer’s amyloid-β (Aβ) deposits extends well beyond the classic Aβ1-40/Aβ1-42 dichotomy, substantially expanded by multiple post-translational modifications that increase the...

    Authors: Agueda Rostagno, Erwin Cabrera, Tammaryn Lashley and Jorge Ghiso
    Citation: Translational Neurodegeneration 2022 11:30
  33. Authors: Federico Rodriguez-Porcel, Kathryn A. Wyman-Chick, Carla Abdelnour Ruiz, Jon B. Toledo, Daniel Ferreira, Prabitha Urwyler, Rimona S. Weil, Joseph Kane, Andrea Pilotto, Arvid Rongve, Bradley Boeve, John-Paul Taylor, Ian McKeith, Dag Aarsland and Simon J. G. Lewis
    Citation: Translational Neurodegeneration 2022 11:29

    The original article was published in Translational Neurodegeneration 2022 11:24

  34. Neurodegenerative diseases are a heterogeneous group of maladies, characterized by progressive loss of neurons. These diseases involve an intricate pattern of cross-talk between different types of cells to mai...

    Authors: Neelam Younas, Leticia Camila Fernandez Flores, Franziska Hopfner, Günter U. Höglinger and Inga Zerr
    Citation: Translational Neurodegeneration 2022 11:28
  35. Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hy...

    Authors: Dongmei Chen, Guihua Lan, Ruomeng Li, Yingxue Mei, Xindong Shui, Xi Gu, Long Wang, Tao Zhang, Chen-Ling Gan, Yongfang Xia, Li Hu, Yuan Tian, Mi Zhang and Tae Ho Lee
    Citation: Translational Neurodegeneration 2022 11:27
  36. Patient-to-patient variability in the degree to which β-amyloid, tau and neurodegeneration impact cognitive decline in Alzheimer’s disease (AD) complicates disease modeling and treatment. However, the underlyi...

    Authors: Christopher Daniel Morrone, Aaron Yenhsin Lai, Jossana Bishay, Mary Elizabeth Hill and JoAnne McLaurin
    Citation: Translational Neurodegeneration 2022 11:26
  37. The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, ass...

    Authors: Federico Rodriguez-Porcel, Kathryn A. Wyman-Chick, Carla Abdelnour Ruiz, Jon B. Toledo, Daniel Ferreira, Prabitha Urwyler, Rimona S. Weil, Joseph Kane, Andrea Pilotto, Arvid Rongve, Bradley Boeve, John-Paul Taylor, Ian McKeith, Dag Aarsland and Simon J. G. Lewis
    Citation: Translational Neurodegeneration 2022 11:24

    The Correction to this article has been published in Translational Neurodegeneration 2022 11:29

  38. There has been a growing appreciation for freezing of gait as a disabling symptom that causes a significant burden in Parkinson’s disease. Previous research has highlighted some of the key components that unde...

    Authors: Simon Lewis, Stewart Factor, Nir Giladi, Alice Nieuwboer, John Nutt and Mark Hallett
    Citation: Translational Neurodegeneration 2022 11:23
  39. Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia. The prevalence of AD is expected to increase as the population ages, placing...

    Authors: Timofey O. Klyucherev, Pawel Olszewski, Alena A. Shalimova, Vladimir N. Chubarev, Vadim V. Tarasov, Misty M. Attwood, Stina Syvänen and Helgi B. Schiöth
    Citation: Translational Neurodegeneration 2022 11:25
  40. Transcriptomic and proteomic profiling of human brain tissue is hindered by the availability of fresh samples from living patients. Postmortem samples usually represent the advanced disease stage of the patien...

    Authors: Salla M. Kangas, Jaakko Teppo, Maija J. Lahtinen, Anu Suoranta, Bishwa Ghimire, Pirkko Mattila, Johanna Uusimaa, Markku Varjosalo, Jani Katisko and Reetta Hinttala
    Citation: Translational Neurodegeneration 2022 11:22
  41. A growing amount of evidence has indicated contributions of variants in causative genes of Parkinson’s disease (PD) to the development of sleep disturbance in PD and prodromal PD stages. In this article, we ai...

    Authors: Jingxuan Huang, Yangfan Cheng, Chunyu Li and Huifang Shang
    Citation: Translational Neurodegeneration 2022 11:21
  42. Alpha-synuclein (α-syn) exhibits pathological misfolding in many human neurodegenerative disorders. We previously showed that α-syn is arginylated in the mouse brain and that lack of arginylation leads to neur...

    Authors: Jun Zhao, Buyan Pan, Marie Fina, Yun Huang, Marie Shimogawa, Kelvin C. Luk, Elizabeth Rhoades, E. James Petersson, Dawei W. Dong and Anna Kashina
    Citation: Translational Neurodegeneration 2022 11:20
  43. Many neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are characterised by the accumulation of misfolded protein deposits in the brain, leading to a progressive destabilisatio...

    Authors: Douglas M. Lopes, Sophie K. Llewellyn and Ian F. Harrison
    Citation: Translational Neurodegeneration 2022 11:19
  44. Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the understanding of this disease, and may b...

    Authors: Chenghuan Song, Jiyun Shi, Pingao Zhang, Yongfang Zhang, Jianrong Xu, Lanxue Zhao, Rui Zhang, Hao Wang and Hongzhuan Chen
    Citation: Translational Neurodegeneration 2022 11:18
  45. Multiple lines of evidence suggest possible impairment of the glymphatic system in amyotrophic lateral sclerosis (ALS). To investigate this, we used in vivo magnetic resonance imaging (MRI) to assess glymphati...

    Authors: Akram Zamani, Adam K. Walker, Ben Rollo, Katie L. Ayers, Raysha Farah, Terence J. O’Brien and David K. Wright
    Citation: Translational Neurodegeneration 2022 11:17
  46. Amyotrophic lateral sclerosis (ALS) is characterized by a progressive loss of motor neurons (MNs), leading to paralysis, respiratory failure and death within 2–5 years of diagnosis. The exact mechanisms of spo...

    Authors: Daehwan Kim, Subin Kim, Ashley Sung, Neetika Patel, Nathan Wong, Michael J. Conboy and Irina M. Conboy
    Citation: Translational Neurodegeneration 2022 11:16

Affiliated with

Annual Journal Metrics

  • 2022 Citation Impact
    12.6 - 2-year Impact Factor
    10.9 - 5-year Impact Factor
    2.072 - SNIP (Source Normalized Impact per Paper)
    2.571 - SJR (SCImago Journal Rank)

    2022 Speed
    7 days submission to first editorial decision for all manuscripts (Median)
    116 days submission to accept (Median)

    2022 Usage
    711,033 downloads
    11,404 Altmetric mentions